Amory John K, Page Stephanie T, Anawalt Bradley D, Matsumoto Alvin M, Bremner William J
Department of Medicine, University of Washington, Box 326429, Seattle, WA 98195, USA.
Contraception. 2007 Mar;75(3):218-23. doi: 10.1016/j.contraception.2006.11.003. Epub 2007 Jan 16.
Testosterone (T) gel, administered transdermally in combination with injections of depomedroxyprogesterone acetate (DMPA) every 3 months, results in effective suppression of spermatogenesis in 90% of men. Men's attitudes regarding the daily self-administration of T-gel and the impact of such a regimen on sexual function, however, are unknown. Therefore, we questioned subjects enrolled in a combination T-gel plus DMPA male contraceptive trial regarding the acceptability of T-gel for male contraception and the impact of the T-gel/DMPA regimen on sexual function and satisfaction during treatment.
Thirty-eight healthy men, ages 18-55, were treated with T-gel (100 mg daily) + DMPA (300 mg every 3 months) for 24 weeks. Sexual function was assessed using a validated questionnaire at baseline, after 12 and 24 weeks of treatment and 12 weeks into recovery. The overall acceptability of the method and attitudes regarding the daily self-administration of T-gel were assessed by a questionnaire 12 weeks into recovery.
Fifty percent of subjects were either satisfied or very satisfied with the T-gel-based contraceptive regimen, and 45% indicated they would use the regimen if it were commercially available. The T-gel was found to be easy to use by 76% of men, but a third of subjects felt that T-gel administration interfered with their daily routine. Sexual function was largely preserved during treatment; however, slight decreases in sexual function were noted during recovery.
The experimental male hormonal contraceptive regimen of T-gel + DMPA is acceptable to approximately one half of study volunteers, most of whom would use the method if it were commercially available. Given its appeal to a significant proportion of men, additional studies using T-gel and DMPA for male contraception are warranted.
睾酮(T)凝胶经皮给药,每3个月联合注射醋酸甲羟孕酮(DMPA),可有效抑制90%男性的精子生成。然而,男性对每日自行使用T凝胶的态度以及这种给药方案对性功能的影响尚不清楚。因此,我们询问了参与T凝胶加DMPA男性避孕试验的受试者,关于T凝胶用于男性避孕的可接受性以及T凝胶/DMPA给药方案在治疗期间对性功能和满意度的影响。
38名年龄在18 - 55岁的健康男性接受T凝胶(每日100毫克)+ DMPA(每3个月300毫克)治疗24周。在基线、治疗12周和24周后以及恢复12周时,使用经过验证 的问卷评估性功能。在恢复12周时通过问卷评估该方法的总体可接受性以及对每日自行使用T凝胶的态度。
50%的受试者对基于T凝胶的避孕方案感到满意或非常满意,45%表示如果该方案上市他们会使用。76% 的男性认为T凝胶易于使用,但三分之一的受试者觉得使用T凝胶会干扰他们的日常生活。治疗期间性功能基本得以保留;然而,在恢复期间注意到性功能略有下降。
T凝胶 + DMPA的实验性男性激素避孕方案约有一半的研究志愿者可以接受,如果上市,他们中的大多数人会使用该方法.鉴于其对相当一部分男性具有吸引力,有必要开展更多使用T凝胶和DMPA进行男性避孕的研究。